Regulated Gene Therapy for Multiple Sclerosis

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Regulated Gene Therapy for Multiple Sclerosis

Postby Dunmann » Thu Feb 09, 2006 7:54 am

Here's an article about a new gene therapy targeted for MS. It sounds very complicated but very interesting. Hopefully we'll see something like this come to fruition in the not too distance future.



http://news.yahoo.com/s/prweb/20060209/ ... eb344333_1



Dunmann.
User avatar
Dunmann
Family Elder
 
Posts: 117
Joined: Sun Oct 02, 2005 3:00 pm

Advertisement

Postby dignan » Thu Feb 09, 2006 9:04 am

I guess I'll add this to the pipeline pre-clinical list...


RheoGene, Inc., announced today that it has granted a commercial license to Ichor Medical Systems for use of its RheoSwitch® Therapeutic System (RTS) in combination with Ichor Medical Systems’ proprietary TriGrid™ Delivery System electroporation technology to develop a gene therapy product for multiple sclerosis.
User avatar
dignan
Family Elder
 
Posts: 1608
Joined: Wed Aug 11, 2004 3:00 pm

Genetic MS

Postby gwa » Fri Feb 10, 2006 11:25 am

Doesn't this therapy indicate a genetic cause for MS? If so, I have not read about such a cause, so this is news to me.

Also, I don't see anything in the article that tells us what this therapy is supposed to do for us.


Please enlighten me.

gwa
User avatar
gwa
Family Elder
 
Posts: 846
Joined: Thu Dec 01, 2005 4:00 pm

Postby raven » Tue Feb 14, 2006 6:06 am

The therapy doesn't indicate a genetic cause for MS, although there is a genetic susceptibility. Genes in the human body control the production of proteins. By causing a gene to overexpress the production of a natural protein can be increased. Ichor medical are looking at causing the body to express higher levels of interferon beta.

Among therapeutic protein programs, Ichor is developing a dramatically improved treatment for multiple sclerosis (MS) patients. The current standard of care for MS is treatment with recombinant interferon beta (rIFN-β) protein wherein patients must be injected multiple times a week and suffer side effects from high interferon levels following treatment. Ichor believes that its TDS / IFN-β therapy will provide several advantages to MS patients, such as once every three months dosing, a more constant level of the protein, thereby reducing side effects, and allow possible combination use with other MS drugs due to the reduced cost of TDS / DNA drug treatment compared to recombinant protein therapies.


If they can bring it to market it should be a step forward.

Robin
Do not go gentle into that good night. Rage, rage against the dying of the light.
User avatar
raven
Family Elder
 
Posts: 240
Joined: Sat Sep 25, 2004 3:00 pm
Location: Bristol, England


Return to General Discussion

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service